Compare SENS & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SENS | RZLT |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.5M | 187.3M |
| IPO Year | N/A | N/A |
| Metric | SENS | RZLT |
|---|---|---|
| Price | $7.81 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $25.58 | $9.14 |
| AVG Volume (30 Days) | 495.3K | ★ 6.6M |
| Earning Date | 03-02-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,298,000.00 | N/A |
| Revenue This Year | $59.55 | N/A |
| Revenue Next Year | $70.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.94 | N/A |
| 52 Week Low | $5.25 | $1.07 |
| 52 Week High | $28.00 | $11.46 |
| Indicator | SENS | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 74.48 | 40.37 |
| Support Level | $6.86 | $2.36 |
| Resistance Level | $7.30 | $2.92 |
| Average True Range (ATR) | 0.44 | 0.27 |
| MACD | 0.15 | 0.32 |
| Stochastic Oscillator | 93.96 | 84.91 |
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.